Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Arginine deiminase with reduced cross-reactivity toward ADI-PEG 20 antibodies for cancer treatment

Arginine deiminase with reduced cross-reactivity toward ADI-PEG 20 antibodies for cancer treatment

US Patent 9789170 · Granted Oct 17, 2017

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Surgical stapling device with powered handle assembly2025
Human pluripotent stem cell-based screening for smooth muscle cell differentiati2025
Protein conjugates2025
Protein conjugates2025
Protein conjugates2025
Reprogramming somatic cells into pluripotent cells using a vector encoding Oct4 2024
Generating arterial endothelial cell populations2023
Expansion and maintenance of adult primary human hepatocytes in culture2023
Generating arterial endothelial cell-seeded vascular grafts2022
Arginine deiminase with reduced cross-reactivity toward ADI - PEG 20 antibodies 2022
Arginine deiminase with reduced cross-reactivity toward ADI - PEG 20 antibodies 2022
Arginine deiminase with reduced cross-reactivity toward ADI - PEG 20 antibodies 2022